Inada, H., Kurano, S., Miyamoto, H., Onishi, M., Suzuki, Y., Narahara, S., Otsuka, F., Iio, E., Watanabe, T., Setoyama, H., Nagaoka, K., Beppu, T., Hayashi, H., & Tanaka, Y. (2025). TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma. Journal of Gastroenterology, 1-9. https://doi.org/10.1007/s00535-025-02320-1
ISO-690 (author-date, English)INADA, Hiroki, KURANO, Sotaro, MIYAMOTO, Hideaki, ONISHI, Masaya, SUZUKI, Yutaka, NARAHARA, Satoshi, OTSUKA, Fumiya, IIO, Etsuko, WATANABE, Takehisa, SETOYAMA, Hiroko, NAGAOKA, Katsuya, BEPPU, Toru, HAYASHI, Hiromitsu und TANAKA, Yasuhito, 2025. TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma. Journal of Gastroenterology. 17 November 2025. P. 1-9. DOI 10.1007/s00535-025-02320-1.
Modern Language Association 9th editionInada, H., S. Kurano, H. Miyamoto, M. Onishi, Y. Suzuki, S. Narahara, F. Otsuka, E. Iio, T. Watanabe, H. Setoyama, K. Nagaoka, T. Beppu, H. Hayashi, und Y. Tanaka. „TP53 Mutation Predicts Resistance to Immune Checkpoint Inhibitor-Based Therapy in Intrahepatic Cholangiocarcinoma“. Journal of Gastroenterology, November 2025, S. 1-9, https://doi.org/10.1007/s00535-025-02320-1.
Mohr Siebeck - Recht (Deutsch - Österreich)Inada, Hiroki/Kurano, Sotaro/Miyamoto, Hideaki/Onishi, Masaya/Suzuki, Yutaka/Narahara, Satoshi u. a.: TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma, Journal of Gastroenterology 2025, 1-9.
Emerald - HarvardInada, H., Kurano, S., Miyamoto, H., Onishi, M., Suzuki, Y., Narahara, S., Otsuka, F., Iio, E., Watanabe, T., Setoyama, H., Nagaoka, K., Beppu, T., Hayashi, H. und Tanaka, Y. (2025), „TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma“, Journal of Gastroenterology, S. 1-9.